CONNAUGHT HOUSE, DUBLIN 4, L2
Reports Third Quarter 2025 Financial Results
Announces Agreement to Acquire Pharmaceuticals, Investor Presentation
Material disclosure
Appoints Joshua Reed as Chief Financial Officer
Investor Presentation
Reports Second Quarter 2025 Financial Results
Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
News, Material Contracts
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
S-8 POS